Tristel PLC
LSE:TSTL
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
350
500
|
Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Tristel PLC
Interest Income Expense
Tristel PLC
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Tristel PLC
LSE:TSTL
|
Interest Income Expense
-ÂŁ15k
|
CAGR 3-Years
57%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Abingdon Health PLC
LSE:ABDX
|
Interest Income Expense
ÂŁ17k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
ConvaTec Group PLC
LSE:CTEC
|
Interest Income Expense
-$99.7m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
||
Inspecs Group PLC
LSE:SPEC
|
Interest Income Expense
-ÂŁ2.5m
|
CAGR 3-Years
5%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
||
Advanced Medical Solutions Group PLC
LSE:AMS
|
Interest Income Expense
ÂŁ2.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Cambridge Nutritional Sciences PLC
LSE:CNSL
|
Interest Income Expense
ÂŁ28k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Tristel PLC
Glance View
Tristel Plc engages in the design, development, manufacture, and sale of infection control, contamination control and hygiene products. The company is headquartered in Snailwell, Cambridgeshire and currently employs 189 full-time employees. The company went IPO on 2005-06-01. The Company’s technology is a chlorine dioxide formulation used by hospitals for the high-level disinfection of medical devices and the sporicidal disinfection of environmental surfaces. The Company’s segments include Hospital medical device decontamination and Hospital environmental surface disinfection. The firm manufactures and sells medical device decontamination products that are used primarily for infection control in hospitals. The firm also manufactures and sells hospital environmental surface disinfection products. The Tristel brand offers airway management, cardiology, ear, nose and throat, ophthalmology, endoscopy, phlebotomy, surfaces, ultrasound, urology, and women's health. The Crystel brand offers pharmaceutical, cosmetic and toiletry (PCT), cleanroom disinfectants and laboratory disinfectants. The company markets its products under the Tristel, Anistel, and Crystel brands.
See Also
What is Tristel PLC's Interest Income Expense?
Interest Income Expense
-15k
GBP
Based on the financial report for Dec 31, 2023, Tristel PLC's Interest Income Expense amounts to -15k GBP.
What is Tristel PLC's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
57%
Over the last year, the Interest Income Expense growth was 92%. The average annual Interest Income Expense growth rates for Tristel PLC have been 57% over the past three years .